Ascendis Pharma A/S ADR [ASND] stock prices are up 1.71% to $212.81 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ASND shares have gain 4.93% over the last week, with a monthly amount glided 1.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on November 18, 2025, when Wolfe Research initiated its Peer Perform rating and assigned the stock a price target of $255. Previously, Raymond James started tracking the stock with Strong Buy rating on October 17, 2025, and set its price target to $271. Morgan Stanley upgraded its rating to an Overweight but stick to its price target of $250 on May 05, 2025. RBC Capital Mkts initiated its recommendation with an Outperform and recommended $205 as its price target on April 16, 2025. UBS started tracking with a Buy rating for this stock on January 07, 2025, and assigned it a price target of $196. In a note dated September 05, 2024, Oppenheimer upgraded an Outperform rating on this stock but restated the target price of $180.
The stock price of Ascendis Pharma A/S ADR [ASND] has been fluctuating between $118.03 and $229.94 over the past year. Currently, Wall Street analysts expect the stock to reach $246.67 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $212.81 at the most recent close of the market. An investor can expect a potential return of 15.91% based on the average ASND price forecast.
Analyzing the ASND fundamentals
The Ascendis Pharma A/S ADR [NASDAQ:ASND] reported sales of 720.68M for trailing twelve months, representing a surge of 292.94%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.54%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is 1.87 and Total Capital is -1.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -4.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 209.94 points at the first support level, and at 207.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 215.93, and for the 2nd resistance point, it is at 219.06.
Ratios To Look Out For
It’s worth pointing out that Ascendis Pharma A/S ADR [NASDAQ:ASND]’s Current Ratio is 1.03. As well, the Quick Ratio is 0.73, while the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 18.04.
Transactions by insiders
Recent insider trading involved JENSEN MICHAEL WOLFF, Officer, that happened on Dec 04 ’25 when 10000.0 shares were purchased. CEO, Jan Moller Mikkelsen completed a deal on Dec 02 ’25 to buy 100000.0 shares. Meanwhile, Officer SPROGOE KENNETT bought 10000.0 shares on Dec 02 ’25.
